Results 211 to 220 of about 753,590 (330)

Targeting m⁶A RNA Modification in Tumor Therapeutics. [PDF]

Curr Oncol
Mao Z, Li M, Wang S.
europepmc   +1 more source

Guide RNAs with 5′ Caps and Novel Box C/D snoRNA-like Domains for Modification of snRNAs in Metazoa [PDF]

, 2004
Kazimierz T. Tycowski, Alar Aab, Joan A. Steitz   +2 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

The Role of <i>N</i>6-Methyladenosine (m6A) RNA Modification in the Pathogenesis of Parkinson's Disease. [PDF]

Biomolecules
Wang Y, Zhao T, Yuan C, Chen X.
europepmc   +1 more source

Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing [PDF]

, 2004
Robert G. Pergolizzi, Ronald G. Crystal
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

5-Methylcytosine RNA modification and its roles in cancer and cancer chemotherapy resistance. [PDF]

J Transl Med
Li F, Liu T, Dong Y, Gao Q, Lu R, Deng Z.   +5 more
europepmc   +1 more source

Modifications of RNA processing modulate the expression of hemoglobin genes.

, 1996
P. Kollia, Eitan Fibach, Sonia M. Najjar, Alan N. Schechter, Constance Tom Noguchi   +4 more
openalex   +1 more source

Effects of RNA polymerase modifications on transcription‐induced negative supercoiling and associated R‐loop formation [PDF]

, 2004
Sonia Broccoli, Fabien Rallu, Patrick Sanscartier, Susana M. Cerritelli, Robert J. Crouch, Marc Drolet   +5 more
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source